TPM1, His, Human

TPM1, His, Human

Tropomyosin-1 (TPM1), a widely expressed actin-binding protein, is downregulated in many tumors and associated with cancer progression. TPM1 overexpression in RCC cell lines can induce tumor cell apoptosis via the p53-mediated mitochondrial pathway. Further studies are needed to fully elucidate the potential of TPM1 as a candidate for RCC targeted therapy in the future.
Z05909
¥69,021.00

Ask us a question
Product Introduction
Species Human
Protein Construction
His TPM1 (Met1-Met284)_x000D_
Accession # NP_000357.3
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 90% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System E.coli
Theoretical Molecular Weight 34.26 kDa
Apparent Molecular Weight The protein has a predicted MW of 34.26 kDa same as Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS, 150mM NaCl (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background Tropomyosin-1 (TPM1), a widely expressed actin-binding protein, is downregulated in many tumors and associated with cancer progression. TPM1 overexpression in RCC cell lines can induce tumor cell apoptosis via the p53-mediated mitochondrial pathway. Further studies are needed to fully elucidate the potential of TPM1 as a candidate for RCC targeted therapy in the future.
Synonyms C15orf13; TMSA; CMD1Y; CMH3; HTM-alpha; LVNC9

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.